title: The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer.
abstract: To determine the relationship between cardiovascular complications of estrogen therapy and fibrinolysis, fibrinolysis parameters plasminogen, urokinase-type plasminogen activator (u-PA), tissue-type plasminogen activator (t-PA), and plasminogen activator inhibitor-1 (PAI-1), were assessed in 12 prostatic cancer patients before and 6 weeks after the onset of estrogen therapy. The levels of plasminogen, u-PA, and PAI-1 in the patients treated with the estrogen therapy were significantly higher than those in the patients before the therapy. The t-PA level in the patients during the therapy was significantly lower than that before the treatment. Cardiovascular complications were found in two patients (16.7%) during estrogen therapy. In the two patients, marked elevation of PAI-1 and decreased level of t-PA were observed during the therapy. These results indicate that cardiovascular complications of estrogen therapy in patients with prostatic cancer may be related to hypofibrinolysis resulting from changes of PAI-1 and t-PA.
authors.affiliation: Department of Urology, Miyazaki Medical College, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Hasui
authors.forename: K
authors.initials: K
authors.lastname: Marutsuka
authors.forename: S
authors.initials: S
authors.lastname: Nishi
authors.forename: S
authors.initials: S
authors.lastname: Kitada
authors.forename: Y
authors.initials: Y
authors.lastname: Osada
authors.forename: A
authors.initials: A
authors.lastname: Sumiyoshi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000097:blood / Q000139:chemically induced* / Q000503:physiopathology; D004967:Estrogens / Q000009:adverse effects* / Q000627:therapeutic use; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000378:metabolism; D015849:Plasminogen Inactivators / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D010959:Tissue Plasminogen Activator / Q000097:blood; D014568:Urokinase-Type Plasminogen Activator / Q000097:blood
chemical_list: D004967:Estrogens; D015849:Plasminogen Inactivators; D010958:Plasminogen; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator